Brazil tells WHA that it supports the health innovation financing

25 May 2010

During the 63th World Health Assembly - which was held in Geneva, Switzerland, - Brazil sought to create innovative mechanisms for financing R&D in the health care sector.

The Brazilian delegation suggested alternatives to finance innovation in health for replacement of the system supported by the pharmaceutical industry, based on the resulting monopoly patents. One of the reports has been conducted by the Brazilian Commission on Public Health and Intellectual Property (CIPIH) of the World Health Organization (WHO).

According to Brazil's Minister of Health, Jose Gomes Temporao, who participated in the assembly, finding innovative ways is crucial to ensuring access to medicines and other products to health priority, particularly for developing countries.

At the meeting, the minister defended instruments such as a global fund for investment in the sector, for instance, taxes paid by the pharmaceutical industry. Thus, he suggested, it could be possible to comprise a larger amount of diseases that today are not covered by this industry.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical